Advertisement

Medical Oncology

, 32:156 | Cite as

The impact of hypoxemia on serum total and free prostate-specific antigen levels in patients with chronic obstructive pulmonary disease

  • Cengiz Ozge
  • Murat BozluEmail author
  • Eylem Sercan Ozgur
  • Mesut Tek
  • Ahmet Tunckiran
  • Necati Muslu
  • Ahmet Ilvan
Original Paper

Abstract

Prostate-specific antigen (PSA) is the most important biochemical marker in the diagnosis and follow-up of patients with prostate cancer. In recent years, a relationship between PSA levels and hypoxic conditions has been described. However, no study has investigated the PSA levels in patients with chronic obstructive pulmonary disease (COPD). The aim of the present study was to investigate the impact of hypoxemia on serum total (tPSA) and free PSA (fPSA) levels in patients with COPD. Between January 2010 and January 2014, 95 male patients who hospitalized for acute exacerbations of COPD and 80 control subjects were enrolled in the study. Serum tPSA and fPSA levels and f/tPSA ratios were determined in all patients on the first day of hospitalization (exacerbation) and 7 days after the treatment (stable state). Statistical analysis included paired t test and Mann–Whitney U test. No statistically significant differences were found between COPD and control groups with regard to the baseline characteristics, except for smoking status. The levels of serum tPSA and fPSA during exacerbation of COPD were significantly higher than the levels of the stable period (p < 0.01), whereas f/tPSA ratio did not change (p > 0.05). Hypoxemia during acute exacerbation of COPD can cause a rise in serum tPSA and fPSA levels, but f/tPSA ratio is not affected. Acute exacerbation of COPD may be added to list of the events in which PSA measurements must be interpreted with caution.

Keywords

Chronic obstructive pulmonary disease Hypoxia Prostate Prostate-specific antigen 

Notes

Conflict of interest

None.

References

  1. 1.
    Heidenreich A, Abrahamsson PA, Artibani W, Catto J, Montorsi F, Van Poppel H, et al. Early detection of prostate cancer: European association of urology recommendation. Eur Urol. 2013;64:347–54.CrossRefPubMedGoogle Scholar
  2. 2.
    Carter HB, Albertsen PC, Barry MC, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419–26.CrossRefPubMedCentralPubMedGoogle Scholar
  3. 3.
    Oesterling JE, Rice DC, Glenski WJ, Bergstralh EJ. Effect of cystoscopy, prostate biopsy and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology. 1993;42:276–82.CrossRefPubMedGoogle Scholar
  4. 4.
    Koller-Strametz J, Fritzer M, Gwechenberger M, Geppert A, Heinz G, Haumer M, et al. Elevation of prostate-specific markers after cardiopulmonary resuscitation. Circulation. 2000;102:290–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Koreny M, Koller-Strametz J, Geppert A, Karth GD, Heinz G, Maurer G, et al. Elevation of prostatic markers following cardiogenic shock. Intensive Care Med. 2001;27:447.CrossRefPubMedGoogle Scholar
  6. 6.
    Netto NR, Lima ML, Guedes MA, Patino LL, De Oliveira JB. Elevation of prostate specific antigen in cardiac surgery with extracorporeal cardiopulmonary circulation. J Urol. 1998;159:875–7.CrossRefGoogle Scholar
  7. 7.
    Global initiative for chronic obstructive lung disease. Pocket Guide to COPD diagnosis, management, and prevention, 2011.Google Scholar
  8. 8.
    Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulm Dis. 2011;6:199–208.Google Scholar
  9. 9.
    Kim V, Benditt JO, Wise RA, Sharafkhaneh A. Oxygen therapy in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:513–8.CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Guvel S, Turkoz R, Egilmez T, Kilinc F, Yaycioglu O, Atalay H, et al. Does ischemia-induced prostate damage during cardiac surgery involving cardiopulmonary bypass cause bladder outlet obstruction? Urol Int. 2005;74:337–40.CrossRefPubMedGoogle Scholar
  11. 11.
    Patane S, Marte F. Prostate-specific antigen kallikrein: from prostate to cardiovascular system. Eur Heart J. 2009;30:1169–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004;59:574–80.CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Jansen FH, Roobol M, Jenster G, Schroder FH, Bangma CH. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol. 2009;55:563–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Stenman UH. Detection of complexes between prostate-specific antigen and protease inhibitors in plasma. Clin Chem. 2010;56:1895–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Agusti AG. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005;2:367–70.CrossRefPubMedGoogle Scholar
  16. 16.
    Patane S, Marte F. Prostate-specific antigen kallikrein and acute myocardial infarction: where we are. Where are we going? Int J Cardiol. 2011;7:e20–2.CrossRefGoogle Scholar
  17. 17.
    Charlesworth MC, Young CY, Miller VM, Tindall DJ. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid. J Androl. 1999;20:220–9.PubMedGoogle Scholar
  18. 18.
    Frenette G, Tremblay RR, Lazure C, Dube JY. Prostatic kallikrein (hk2), but not prostate-specific antigen (hk3), activates single-chain urokinase-type plasminogen activator. Int J Cancer. 1997;71:897–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Hoiseth AD, Omland T, Hagve TA, Brekke PH, Soyseth V. Determinants of high-sensitive cardiac troponin T during acute exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. BMC Pulm Med. 2012;6:22.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Cengiz Ozge
    • 1
  • Murat Bozlu
    • 2
    Email author
  • Eylem Sercan Ozgur
    • 1
  • Mesut Tek
    • 2
  • Ahmet Tunckiran
    • 4
  • Necati Muslu
    • 3
  • Ahmet Ilvan
    • 1
  1. 1.Department of Chest DiseasesUniversity of Mersin School of MedicineMersinTurkey
  2. 2.Department of UrologyUniversity of Mersin School of MedicineMersinTurkey
  3. 3.Department of BiochemistryUniversity of Mersin School of MedicineMersinTurkey
  4. 4.Department of Urology, Faculty of Medicine, Alanya Practice and Research CenterBaskent UniversityAlanyaTurkey

Personalised recommendations